Literature DB >> 9710679

Infection in the intensive care unit: beta-lactamase-mediated resistance among Enterobacteriaceae and optimal antimicrobial dosing.

G L Drusano1.   

Abstract

Class I beta-lactamase-mediated resistance in Enterobacteriaceae is increasingly common, clinically important, and often associated with previous use of third-generation cephalosporins. Extended-spectrum beta-lactamases that confer resistance to third-generation cephalosporins are also becoming more widespread. Beta-lactamase-producing organisms often display multiresistance, and this has been associated with increased mortality among patients. For all beta-lactam antimicrobials, the time that the plasma concentration exceeds the minimum inhibitory concentration (MIC) is the principal factor determining antibacterial activity. For concentration-dependent antimicrobials such as aminoglycosides and fluoroquinolones, the area under the plasma-concentration time curve:MIC ratio is the variable that has the strongest link to clinical outcome, particularly when relatively low peak: MIC values (< 10:1) are achieved. Peak concentration is of major concern for suppression of resistance. When high peak: MIC ratios (> or = 10:1) are achieved, this may suppress resistance and become the primary variable linked to outcome. When designing antimicrobial dosage regimens, it is important to take into account the pharmacodynamics of the drug in order to maximize the potential for achieving a positive clinical outcome and suppressing the emergence of bacterial resistance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9710679     DOI: 10.1086/514915

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  6 in total

Review 1.  Drug resistance in intensive care units.

Authors:  W C Albrich; M Angstwurm; L Bader; R Gärtner
Journal:  Infection       Date:  1999       Impact factor: 3.553

Review 2.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

Review 3.  Clinical role of beta-lactam/beta-lactamase inhibitor combinations.

Authors:  Nelson Lee; Kwok-Yung Yuen; Cyrus R Kumana
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  Point prevalence of appropriate antimicrobial therapy in a Dutch university hospital.

Authors:  H Akhloufi; R H Streefkerk; D C Melles; J E M de Steenwinkel; C A M Schurink; R P Verkooijen; C P van der Hoeven; A Verbon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-05-28       Impact factor: 3.267

5.  Antimicrobial breakpoint estimation accounting for variability in pharmacokinetics.

Authors:  Goue Denis Gohore Bi; Jun Li; Fahima Nekka
Journal:  Theor Biol Med Model       Date:  2009-06-26       Impact factor: 2.432

6.  Pharmacokinetics of ceftiofur in healthy and lipopolysaccharide-induced endotoxemic newborn calves treated with single and combined therapy.

Authors:  Feray Altan; Kamil Uney; Ayse Er; Gul Cetin; Burak Dik; Enver Yazar; Muammer Elmas
Journal:  J Vet Med Sci       Date:  2017-06-05       Impact factor: 1.267

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.